Idasanutlin and venetoclax in elderly R/R AML

Venetoclax for elderly AML patientsПодробнее

Current research in elderly, untreated AML: venetoclax combinationsПодробнее

Venetoclax plus idasanutlin for R/R AML: Phase I/II trialПодробнее

Venetoclax Combination Therapy and Elderly AML PatientsПодробнее

Venetoclax combinations effective in elderly AMLПодробнее

Venetoclax-Based Combination Therapies Revolutionize Paradigm for Elderly AMLПодробнее

Oral combination of HMAs + venetoclax in unfit or elderly patients with AMLПодробнее

Exciting novel AML treatment: venetoclax plus cobimetinib or idasanutlin in elderly patientsПодробнее

Naval Daver, ASH 2019: Venetoclax in Combination with Idasanutlin in Relapsed or Refractory AMLПодробнее

Venetoclax plus CLAD/LDAC and aza for older AML patientsПодробнее

Venetoclax in AML updates: approval & combinationsПодробнее

Promising results for venetoclax combination therapies in elderly AMLПодробнее

Outcomes and options for R/R AML patients who fail venetoclax-based salvage therapyПодробнее

Update on venetoclax combination trials for elderly AML from ASH 2017Подробнее

Novel approaches to treating AML in elderly patientsПодробнее

CAVEAT: venetoclax and high dose chemo for elderly AMLПодробнее

Managing AML in elderly patientsПодробнее

The challenge of treating elderly patients with AML with venetoclax plus azacitidineПодробнее

Treatment approaches for elderly/unfit patients with AML ineligible for intensive chemotherapyПодробнее